Objective:To observe the efficacy and safety of BD (bortezomib, dexamethasone) regimen and PCD (bortezomib, cyclophosphamide, dexamethasone) regimen in treatment of multiple myeloma (MM).Methods:The clinical data of 31 patients with MM treated in Huangshan People's Hospital of Anhui Province from January 2015 to October 2019 were retrospectively analyzed. The patients were divided into BD group (11 cases) and PCD group (20 cases) according to different treatment schemes. The treatment efficacy and adverse reactions of the two groups were compared.Results:MM patients were treated with BD and PCD regimens for 2-6 courses, with a total response rate of 83.9% (26/31) and a median onset time of 2.5 months (1.3-6.2 months). Among them, there were 2 cases of complete remission (CR), 4 cases of very good partial remission (VGPR), 2 cases of partial remission (PR), 2 cases of stable disease (SD), and 1 case of progression of disease (PD) in the BD group; in the PCD group, there were 6 cases of CR, 8 cases of VGPR, 4 cases of PR, 1 case of SD, and 1 case of PD; there was no statistically significant difference in clinical efficacy between the two groups ( χ2 = 0.186, P = 0.758). There were 1 case of leukopenia, 1 case of anemia, 1 case of thrombocytopenia, 1 case of liver damage, 3 cases of neurological adverse reactions, 2 cases of pulmonary infection, 2 cases of diarrhea in the BD group; there were 3 cases of leukopenia, 1 case of anemia, 3 cases of thrombocytopenia, 1 case of liver damage, 5 cases of neurological adverse reactions, 4 cases of pulmonary infection and 3 cases of diarrhea in the PCD group; there was no significant difference in adverse reactions between the two groups ( P > 0.05). Conclusions:The bortezomib-based combined chemotherapy regimens can achieve CR and VGPR for MM patients in a short time, and effectively delay the disease progression. The efficacy of the three-drug combination regimen may be better than the two-drug combination regimen.